Newcastle University

Publications

Year: 2013 2012 2011 2010 2009 2008 2007 2006 2005 2004 2003 2002 2001 2000 1999 1998 1997 1996 1995 1994 1993 1992 1991 1990 1989 1988 1987 1986 1984 1983 1980 1979

• Murr M, Cano C, Golding BT, Hardcastle IR, Hummersome M, Frigerio M, Curtin NJ, Menear K, Richardson C, Smith G, Griffin R. 8-Biarylchromen-4-one inhibitors of the DNA-dependent protein kinase (DNA-PK). Bioorganic and Medicinal Chemistry Letters 2008, 18(17), 4885-4890.
• Allan JM, Sunter N, Hall A, Mainou-Fowler T, Jackson G, Summerfield G, Harris RJ, Pettitt A, Houlston R, Bailey J, Pepper C, Fegan C, Pratt G, Allsup DJ. A Common Genetic Variant in the 3'UTR of IRF4/MUM1 Associates with Risk of Disease and Poor Prognosis in Chronic Lymphocytic Leukaemia. In: Blood: 50th Annual Meeting of the American Society of Hematology. 2008, San Francisco, California, USA: American Society of Hematology.
• Syed AA, Halpin C, Irving JAE, Unwin NC, White M, Bhopal RS, Redfern CPF, Weaver JU. A common intron 2 polymorphism of the glucocorticoid receptor gene is associated with insulin resistance in men. Clinical Endocrinology 2008, 68(6), 879-884.
• Onel K, Knight JA, Skol AD, Tennant TR, Banerjee M, Walgren R, Shao J, Allan JM, Le Beau MM, Larson RA, Graubert T, Cox NJ. A Genome-Wide Analysis to Identify Novel Susceptibility Loci for Therapy-Related Acute Myeloid Leukemia. In: Blood: 50th Annual Meeting of the American Society of Hematology. 2008, San Francisco, California, USA: American Society of Hematology.
• Di Bernardo M, Crowther-Swanepoel D, Broderick P, Webb E, Sellick G, Wild R, Sullivan K, Vijayakrishnan J, Wang Y, Pittman A, Sunter N, Hall AG, Dyer M, Matutes E, Dearden C, Mainou-Fowler T, Jackson GH, Summerfield G, Harris R, Pettitt A, Hillmen P, Allsup D, Bailey J, Pratt G, Pepper C, Fegan C, Allan JM, Catovsky D, Houlston R. A genome-wide association study identifies six susceptibility loci for chronic lymphocytic leukemia. Nature Genetics 2008, 40(10), 1204-1210.
• McCracken SRC, Ramsay A, Heer R, Mathers ME, Jenkins BL, Edwards J, Robson CN, Marquez R, Cohen P, Leung HY. Aberrant expression of extracellular signal-regulated kinase 5 in human prostate cancer. Oncogene 2008, 27(21), 2978-2988.
• James R, Lightfoot T, Simpson J, Moorman AV, Roman E, Kinsey S. Acute leukemia in children with Down's syndrome: the importance of population based study. Haematologica 2008, 93(8), 1262-1263.
• Beale GS, Chattopadhyay D, Gray J, Stewart SF, Hudson M, Day CP, Trerotoli P, Giannelli G, Manas DM, Reeves HL. AFP, PIVKAII, GP3, SCCA-1 and follisatin as surveillance biomarkers for hepatocellular cancer in non-alcoholic and alcoholic fatty liver disease. BMC Cancer 2008, 8, 200.
• Cork DMW, Lennard TWJ, Tyson-Capper AJ. Alternative splicing and the progresterone receptor in breast cancer. Breast Cancer Research 2008, 10(3), 207.
• Riedinger C, Endicott JA, Kemp SJ, Smyth LA, Watson A, Valeur E, Golding BT, Griffin RJ, Hardcastle IR, Noble ME, McDonnell JM. Analysis of Chemical Shift Changes Reveals the Binding Modes of Isoindolinone Inhibitors of the MDM2-p53 Interaction. Journal of the American Chemical Society 2008, 130(47), 16038-16044.
• Rogerson LC, Darby S, Jabbar TA, Mathers ME, Leung HY, Robson CN, Sahadevan K, O'Toole KT, Gnanapragasam VJ. Application of transcript profiling in formalin-fixed paraffin-embedded diagnostic prostate cancer needle biopsies. BJU International 2008, 102(3), 364-370.
• Sim E, Sandy J, Evangelopoulos D, Fullam E, Bhakta S, Westwood I, Krylova A, Lack N, Noble MEM. Arylamine N-acetyltransferases in mycobacteria. Current Drug Metabolism 2008, 9(6), 510-519.
• Darby S, Cross SS, Brown NJ, Hamdy F, Robson CN. BMP-6 over-expression in prostate cancer is associated with increased Id-1 protein and a more invasive phenotype. Journal of Pathology 2008, 214(3), 394-404.
• Clark EL, Fuller-Pace FV, Elliott DJ, Robson CN. Coupling transcription to RNA processing via the p68 DEAD box RNA helicase androgen receptor co-activator in prostate cancer. Biochemical Society Transactions 2008, 36(3), 546-547.
• Bettayeb K, Oumata N, Echalier A, Ferandin Y, Endicott JA, Galons H, Meijer L. CR8, a potent and selective, roscovitine-derived inhibitor of cyclin-dependent kinases. Oncogene 2008, 27(44), 5797-5807.
• Moorman AV, Richards SM, Hancock JP, Mitchell CD, Vora AJ, Harrison CJ, Goulden NJ. Cytogenetic-specific heterogeneity in the kinetics of minimal residual disease (MIRD) clearance in childhood lymphoblastic leukaemia (ALL). In: 48th Annual Scientific Meeting of the British Society of Haematology, incorporating the 6th Bi-Annual I-BFM Leukaemia Symposium. 2008, Glasgow: British Journal of Haematology: Wiley-Blackwell.
• Moss SF, Lee JW, Sabo E, Rubin AK, Rommel J, Westley BR, May FEB, Gao J, Meitner PA, Tavares R, Resnick MB. Decreased expression of gastrokine 1 and the trefoil factor interacting protein TFIZ1/GKN2 in gastric cancer: Influence of tumor histology and relationship to prognosis. Clinical Cancer Research 2008, 14(13), 4161-4167.
• Lu X, Vogt P, Boger D, Lunec J. Disruption of the MYC transcriptional function by a small-molecule antagonist of MYC/MAX dimerization. Oncology Reports 2008, 19(3), 825-830.
• Fullam E, Westwood IM, Anderton MC, Lowe ED, Sim E, Noble MEM. Divergence of cofactor recognition across evolution: Coenzyme a binding in a prokaryotic arylamine N-acetyltransferase. Journal of Molecular Biology 2008, 375(1), 178-191.
• Willmore E, Elliott SL, Mainou-Fowler T, Summerfield GP, Jackson GH, O'Neill F, Lowe C, Carter A, Harris R, Pettitt AR, Cano-Soumillac C, Griffin RJ, Cowell IG, Austin CA, Durkacz BW. DNA-dependent protein kinase is a therapeutic target and an indicator of poor prognosis in B-cell chronic lymphocytic leukemia. Clinical Cancer Research 2008, 14(12), 3984-3992.
• Alferez D, Wilkinson RW, Watkins J, Poulsom R, Mandir N, Wedge SR, Pyrah IT, Smith NR, Jackson L, Ryan AJ, Goodlad RA. Dual inhibition of VEGFR and EGFR signaling reduces the incidence and size of intestinal adenomas in ApcMin/+ mice. Molecular Cancer Therapeutics 2008, 7(3), 590-598.
• Heer R, Robson CN. Editorial comment on: Delta-like 1 (Dlk-1), a novel marker of prostate basal and candidate epithelial stem cells, is downregulated by notch signalling in intermediate/transit amplifying cells of the human prostate. European Urology 2008, 54(6), 1353-1353.
• Jobson, A., Willmore, E., Tilby, M.J., Mistry, P., Charlton, P, Austin, C. Effect of phenazine compounds XR11576 and XR5944 on DNA topoisomerases. Cancer Chemotherapy and Pharmacology 2008, 63(5), 1-13.
• Bradley DP, Tessier JL, Checkley D, Kuribayashi H, Waterton JC, Kendrew J, Wedge SR. Effects of AZD2171 and vandetanib (ZD6474, Zactima) on haemodynamic variables in an SW620 human colon tumour model: an investigation using dynamic contrast-enhanced MRI and the rapid clearance blood pool contrast agent, P792 (gadomelitol). NMR in Biomedicine 2008, 21(1), 42-52.
• Chinnaswamy G, Cole M, Boddy AV, Keir M, Price L, Parry AP, English M, Veal GJ. Estimation of renal function and its potential impact on carboplatin dosing in children with cancer. British Journal of Cancer 2008, 99(6), 894-899.
• Wilkinson S, Kucukmetin A, Cross P, Darby S, Gnanapragasam V, Calvert AH, Robson C, Edmondson RJ. Expression of gonadotrophin releasing hormone receptor I is a favorable prognostic factor in epithelial ovarian cancer. Human Pathology 2008, 39(8), 1197-1204.
• Lochan R, Daly AK, Reeves HL, Charnley RM. Genetic susceptibility in pancreatic ductal adenocarcinoma. British Journal of Surgery 2008, 95(1), 22-32.
• Allan JM. Genetic susceptibility to radiogenic cancer in humans. Health Physics 2008, 95(5), 677-686.
• Scott K, Adamson PJ, Willett EV, Worrillow LJ, Allan JM. Genetic variation in genes expressed in the germinal center and risk of B cell lymphoma among Caucasians. Haematologica 2008, 93(10), 1597-600.
• Anderton JA, Lindsey JC, Lusher ME, Gilbertson RJ, Bailey S, Ellison DW, Clifford SC. Global analysis of the medulloblastoma epigenome identifies disease-subgroup-specific inactivation of COL1A2. Neuro-oncology 2008, 10(6), 981-994.
• Reeves EP, Ali T, Leonard P, Hearty S, O'Kennedy R, May FEB, Westley BR, Josenhans C, Rust M, Suerbaum S, Smith A, Drumm B, Clyne M. Helicobacter pylori Lipopolysaccharide Interacts With TFF1 in a pH-Dependent Manner. Gastroenterology 2008, 135(6), 2043-2054.
• Rostron AJ, Avlonitis VS, Cork DMW, Grenade DS, Kirby JA, Dark JH. Hemodynamic Resuscitation With Arginine Vasopressin Reduces Lung Injury After Brain Death in the Transplant Donor. Transplantation 2008, 85(4), 597-606.
• Strefford JC, An Q, Wright SL, Konn ZJ, Matheson E, Minto L, Parker H, Moorman AV, Hall A, Irving J, Harrison CJ. Heterogeneous breakpoints target PAX5 in acute lymphoblastic leukaemia patients with dicentric chromosomes. In: Abstracts of the British Society of Haematology 48th Annual Scientific Meeting, incorporating the 6th Bi-Annual I-BFM Leukaemia Symposium. 2008, Glasgow, UK: British Journal of Haematology: Wiley-Blackwell Publishing Ltd.
• Russell L, Harrison CJ. IDENTIFICATION OF MULTIPLE NOVEL IGH@ TRANSLOCATIONS IN ADOLESCENT ACUTE LYMPHOBLASTIC LEUKAEMIA. Haematologica: the hematology journal 2008, 93(S1), 197-198.
• Russell LJ, Capasso M, Vater I, Moorman AV, Akasaka T, Harder L, Heidenreich O, Machado L, Gest S, Strefford JC, Chandrasekaran T, Tonnies H, Majid A, Bernard O, Dyer MJS, Siebert R, Harrison CJ. IGH@ Translocations Involving the Pseudoautosomal Region 1 (PAR1) of Both Sex Chromosomes Deregulate the Cytokine Receptor-Like Factor 2 (CRLF2) Gene in B Cell Precursor Acute Lymphoblastic Leukemia (BCP-ALL). In: Abstracts of the 50th Annual Meeting of the American Society of Hematology. 2008, San Francisco, CA: Blood: American Society of Hematology.
• le Viseur C, Hotfilder M, Bomken S, Wilson K, Röttgers S, Schrauder A, Rosemann A, Irving JAE, Stam R, Shultz L, Harbott J, Jürgens H, Schrappe M, Pieters R, Vormoor HJ. In Childhood Acute Lymphoblastic Leukemia, Blasts at Different Stages of Immunophenotypic Maturation Have Stem Cell Properties. Cancer Cell 2008, 14(1), 47-58.
• Wilson K, Rehe K, Bomken S, Case M, Shultz L, Irving J, Vormoor J. In Childhood ALL, Both Blasts with a CD20(-/Low) and a CD20(High) Immunophenotype, Have the Ability to Transfer the Leukemia Onto Immune-Deficient NOD/Scid Y-/- Mice. In: Blood: 50th Annual Meeting of the American Society of Hematology. 2008, San Francisco, California, USA: American Society of Hematology.
• Davison Z, Dutkowski C, Gee JMW, Nicholson RI, Thomas CP, Heard CM. In Vitro Effects on MCF-7 Breast Cancer Cells Of Signal Transduction Inhibitor/Tamoxifen/Eicosapentaenoic Acid Combinations and their Simultaneous Delivery Across Skin. Pharmaceutical Research 2008, 25(11), 2516-2525.
• Moorman AV, Sulong S, Irving JAE, Strefford JC, Case MC, Minto CLJ, Harrison CJ, Hall AG. Inactivation of CDKN2A in childhood acute lymphoblastic leukaemia (ALL) occurs principally by deletion and is strongly correlated with cytogenetic subgroups. In: British Society of Haematology 48th Annual Scientific Meeting, incorporating the 6th Bi-Annual I-BFM Leukaemia Symposium. 2008, Glasgow, UK: Wiley-Blackwell Publishing Ltd.
• Ryk C, Routledge MN, Allan JM, Wild CP, Kumar R, Lambert B, Hou S. Influence of DNA repair gene polymorphisms on the initial repair of MMS-induced DNA damage in human lymphocytes as measured by the alkaline comet assay. Environmental and Molecular Mutagenesis 2008, 49(9), 669-675.
• Williams KJ, Telfer BA, Shannon AM, Babur M, Stratford IJ, Wedge SR. Inhibition of vascular endothelial growth factor signalling using cediranib (RECENTIN; AZD2171) enhances radiation response and causes substantial physiological changes in lung tumour xenografts. British Journal of Radiology 2008, 81(Special issue 1), S21-S27.
• Curwen JO, Musgrove HL, Kendrew J, Richmond GHP, Ogilvie DJ, Wedge SR. Inhibition of vascular endothelial growth factor-A signaling induces hypertension: examining the effect of cediranib (RECENTIN; AZD2171) treatment on blood pressure in rat and the use of concomitant antihypertensive therapy. Clinical Cancer Research 2008, 14(10), 3124-3131.
• Kool M, Koster J, Bunt J, Hasselt N, Lakeman A, van Sluis P, Troost D, Schouten-van Meeteren N, Caron H, Cloos J, Mršić A, Ylstra B, Grajkowska W, Hartmann W, Pietsch T, Ellison DW, Clifford SC, Versteeg R. Integrated genomics identifies five medulloblastoma subtypes with distinct genetic profiles, pathway signatures and clinicopathological features. PLoS ONE 2008, 3(8), e3088.
• Rand V, Prebble E, Ridley L, Howard M, Wei W, Brundler MA, Fee BE, Riggins GJ, Coyle B, Grundy RG. Investigation of chromosome 1q reveals differential expression of members of the S100 family in clinical subgroups of intracranial paediatric ependymoma. British Journal of Cancer 2008, 99(7), 1136-1143.
• Ellis NA, Huo D, Yildiz O, Worrillow LJ, Banerjee M, Le Beau MM, Larson RA, Allan JM, Onel K. MDM2 SNP309 and TP53 Arg72Pro interact to alter therapy-related acute myeloid leukemia susceptibility. Blood 2008, 112(3), 741-749.
• Watson AF, Golding BT, Griffin RJ, Hutton C, Liu JF, Lug XH, Lunec J, Newell DR, Valeur E, Hardcastle IR. MEDI 147-Isoindolinone-based inhibitors of the MDM2-p53 protein-protein interaction. In: Abstracts of Papers of the American Chemical Society: 236th National Meeting of the American Chemical Society. 2008, Philadelphia, Pennsylvania, USA: American Chemical Society.
• Pizer B, Clifford SC. Medulloblastoma: new insights into biology and treatment. Archives of Disease in Childhood - Education and Practice 2008, 93(5), 137-44.
• Echalier A, Bettayeb K, Ferandin Y, Lozach O, Clement M, Valette A, Liger F, Marquet B, Morris JC, Endicott JA, Joseph B, Meijer L. Meriolins (3-(pyrimidin-4-yl)-7-azaindoles): Synthesis, kinase inhibitory activity, cellular effects, and structure of a CDK2/cyclin A/meriolin complex. Journal of Medicinal Chemistry 2008, 51(4), 737-751.
• Matheson EC, Cole M, Wilkins BS, Hall AG. Mismatch repair defects in childhood acute lymphoblastic leukaemia at diagnosis and relapse. In: The British Society of Haematology 48th Annual Scientific Meeting, incorporating the 6th Bi-Annual I-BFM Leukaemia Symposium. 2008, Glasgow, UK: British Journal of Haematology: Wiley-Blackwell Publishing Ltd.
• Jamieson D. Mitomycin C. In: Schwab, M, ed. Encyclopedia of Cancer. Berlin: Springer-Verlag, 2008.
• Allan JM , Shorto J, Adlard J, Bury J, Coggins R, George R, Katory M, Quirke P, Richman S, Scott D, Scott K, Seymour M, Travis LB, Worrillow LJ, Bishop DT, Cox A. MLH1 -93G>A promoter polymorphism and risk of mismatch repair deficient colorectal cancer. International Journal of Cancer 2008, 123(10), 2456-2459.
• Todd R, Lunec J. Molecular pathology and potential therapeutic targets in soft-tissue sarcoma. Expert Review of Anticancer Therapy 2008, 8(6), 939-948.
• Ridley L, Rahman R, Brundler MA, Ellison D, Lowe J, Robson K, Prebble E, Luckett I, Gilbertson RJ, Parkes S, Rand V, Coyle B, Grundy RG. Multifactorial analysis of predictors of outcome in pediatric intracranial ependymoma. Neuro-Oncology 2008, 10(5), 675-689.
• Case MC, Matheson E, Minto L, Hassan R, Harrison CJ, Bown NP, Bailey S, Vormoor J, Hall AG, Irving JAE. Mutation of genes affecting the RAS pathway is common in childhood acute lymphoblastic leukemia. Cancer Research 2008, 68(16), 6803-6809.
• Gomaa MS, Armstrong JL, Bobillon B, Veal GJ, Brancale A, Redfern CPF, Simons C. Novel azolyl-(phenylmethyl)]aryl/heteroarylamines: Potent CYP26 inhibitors and enhancers of all-trans retinoic acid activity in neuroblastoma cells. Bioorganic and Medicinal Chemistry 2008, 16(17), 8301-8313.
• Moorman AV. One man's dose, another man's poison. Blood 2008, 111(7), 3303-3304.
• O'Hara J, Lock C, Paleri V, Wight R. Oral feeding regimes following laryngectomy - A qualitative study of consultants' opinions in the North of England. Oral Oncology 2008, 45(8), 727-730.
• Calvert AH, Plummer ER, Curtin NJ, Edmondson RJ, Drew Y. PARP inhibitors in cancer treatment. In: 20th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics. 2008, Geneva, Switzerland: European Journal of Cancer Supplements: Pergamon.
• Plummer ER, Jones C, Middleton M, Wilson R, Evans J, Olsen A, Curtin NJ, Boddy AV, McHugh P, Newell DR, Harris A, Johnson P, Steinfeldt H, Dewji R, Wang D, Robson L, Calvert AH. Phase I study of the poly(ADP-ribose) polymerase inhibitor, AG014699, in combination with temozolomide in patients with advanced solid tumors. Clinical Cancer Research 2008, 14(23), 7917-7923.
• Worrillow LJ, Smith AG, Scott K, Andersson M, Ashcroft AJ, Dores GM, Glimelius B, Holowaty E, Jackson GH, Jones GL, Lynch CF, Morgan G, Pukkala E, Scott D, Storm HH, Taylor PR, Vyberg M, Willett E, Travis LB, Allan JM. Polymorphic MLH1 and risk of cancer after methylating chemotherapy for Hodgkin lymphoma. Journal of Medical Genetics 2008, 45(3), 142-146.
• Paleri V, Robinson M, Bradley P. Polymorphous low-grade adenocarcinoma of the head and neck. Current Opinion in Otolaryngology and Head and Neck Surgery 2008, 16(2), 163-169.
• Mondick JT, Gibiansky L, Gastonguay MR, Skolnik JM, Cole M, Veal GJ, Boddy AV, Adamson PC, Barrett JS. Population pharmacokinetic investigation of actinomycin D in children and young adults. Journal of Clinical Pharmacology 2008, 48(1), 35-42.
• Morgan GJ, Davies FE, Cavenagh JD, Jackson GH. Position statement on the use of bortezomib in multiple myeloma. International Journal of Laboratory Hematology 2008, 30(1), 1-10.
• Jennings NA, Griffin SM, Lamb PJ, Preston S, Richardson D, Karat D, Hayes N. Prospective study of bone scintigraphy as a staging investigation for oesophageal carcinoma. British Journal of Surgery 2008, 95(7), 840-844.
• Paleri V, Kelly CG. Re-irradiation with concurrent chemotherapy in recurrent head and neck cancer: A decision analysis model based on a systematic review. Clinical Otolaryngology 2008, 33(4), 331-337.
• Rajan P, Gaughan L, Dalgliesh C, El-Sherif A, Robson CN, Leung HY, Elliott DJ. Regulation of gene expression by the RNA-binding protein Sam68 in cancer. Biochemical Society Transactions 2008, 36(3), 505-507.
• Howard R, Gilbert E, Lynch C, Hall P, Storm H, Holowaty E, Pukkala E, Langmark F, Kaijser M, Andersson M, Joensuu H, Fossa S, Allan JM, Travis L. Risk of Leukemia Among Survivors of Testicular Cancer: A Population-based Study of 42,722 Patients. Annals of Epidemiology 2008, 18(5), 416-421.
• López-Lázaro M, Willmore E, Elliott SL, Austin CA. Selenite induces topoisomerase I and II-DNA complexes in K562 leukemia cells. International Journal of Cancer 2008, 123(9), 2217-2221.
• Binda O, Nassif C, Branton PE. SIRT1 negatively regulates HDAC1-dependent transcriptional repression by the RBP1 family of proteins. Oncogene 2008, 27(24), 3384-3392.
• Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A, Schwartz M, Porta C, Zeuzem S, Bolondi L, Greten TF, Galle PR, Seitz JF, Borbath I, Häussinger D, Giannaris T, Shan M, Moscovici M, Voliotis D, Bruix J. Sorafenib in advanced hepatocellular cancer. N Engl J Med 2008, 359, 378-90.
• Rowe JM, Buck G, Moorman AV, Tallman MS, Richards SM, Fielding AK, Burnett AK, Franklin IM, Wiernik PH, Lazarus HM, Paietta E, Litzow MR, Marks DI, Luger S, Dewald GW, Goldstone AH. Standard Consolidation/Maintenance Chemotherapy Is Consistently Superior to a Single Autologous Transplant for Adult Patients with Acute Lymphoblastic Leukemia: Results of the International ALL Trial (MRC UKALL XII/ECOG E2993). In: Abstracts of the 50th Annual Meeting of the American Society of Hematology. 2008, San Francisco, CA: Blood: American Society of Hematology.
• Lorenz S, Vakonakis I, Lowe ED, Campbell ID, Noble MEM, Hoellerer MK. Structural Analysis of the Interactions Between Paxillin LD Motifs and alpha-Parvin. Structure 2008, 16(10), 1521-1531.
• Lack N, Lowe ED, Lui J, Eltis LD, Noble MEM, Sim E, Westwood IM. Structure of HsaD, a steroid-degrading hydrolase, from Mycobacterium tuberculosis. Acta Crystallographica. Section F: Structural Biology and Crystallization Communications 2008, 64(1), 2-7.
• Merckx A, Echalier A, Langford K, Sicard A, Langsley G, Joore J, Doerig C, Noble M, Endicott J. Structures of P. falciparum protein kinase 7 identify an activation motif and leads for inhibitor design. Structure 2008, 16(2), 228–238.
• Foote KM, Mortlock AA, Heron NM, Jung FH, Hill GB, Pasquet G, Brady MC, Green S, Heaton SP, Kearney S, Keen NJ, Odedra R, Wedge SR, Wilkinson RW. Synthesis and SAR of 1-acetanilide-4-aminopyrazole-substituted quinazolines: selective inhibitors of Aurora B kinase with potent anti-tumor activity. Bioorganic & Medicinal Chemistry Letters 2008, 18(6), 1904-1909.
• Russell LJ, Akasaka T, Majid A, Sugimoto KJ, Karran EL, Nagel I, Harder L, Claviez A, Gesk S, Moorman AV, Ross F, Mazzullo H, Strefford JC, Siebert R, Dyer MJS, Harrison C. t(6;14)(p22;q32): a new recurrent IGH@ translocation involving ID4 in B-cell precursor acute lymphoblastic leukemia (BCP-ALL). Blood 2008, 111(1), 387-391.
• Mckie C, Ahmad UA, Fellows S, Meikle D, Stafford FW, Thomson PJ, Welch AR, Paleri V. The 2-week rule for suspected head and neck cancer in the United Kingdom: Referral patterns., diagnostic efficacy of the guidelines and compliance. Oral Oncology 2008, 44(9), 851-856.
• Parker H, An Q, Barber K, Case MC, Davies TL, Konn Z, Stewart A, Wright S, Griffiths M, Ross FM, Moorman AV, Hall AG, Irving JAE, Harrison CJ, Strefford JC. The complex genomic profile of ETV6-RUNX1 positive acute lymphoblastic leukemia highlights a recurrent deletion of TBL1XR1. Genes, Chromosomes and Cancer 2008, 47(12), 1118-1125.
• Oozeer NB, Benbow J, Downs C, Kelly C, Welch A, Paleri V. The effect of comorbidity on quality of life during radiotherapy in head and neck cancer. Otolaryngology - Head and Neck Surgery 2008, 139(2), 268-272.
• Rego A, Sinclair PB, Tao W, Kireev I, Bemont AS. The facultative heterochromatin of the inactive X chromosome has a distinctive condensed ultrastructure. Journal of Cell Science 2008, 121(7), 1119-1127.
• Allan JM. The Genetics of Cancer Survivorship. Hematology/Oncology Clinics of North America 2008, 22(2), 257-269.
• Miele L, Beale G, Patman G, Nobili V, Leathart J, Grieco A, Abate M, Friedman S, Narla G, Bugianesi E, Day C, Reeves H. The Kruppel-like factor 6 genotype is associated with fibrosis in nonalcoholic fatty liver disease. Gastroenterology 2008, 135(1), 282-291.e1.
• Clark EL, Coulson AC, Dalgliesh C, Rajan P, Nicol SM, Fleming S, Heer R, Gaughan L, Leung HY, Elliott DJ, Fuller-Pace FV, Robson CN. The RNA helicase p68 is a novel androgen receptor coactivator involved in splicing and is overexpressed in prostate cancer. Cancer Research 2008, 68(19), 7938-7946.
• Rajan P, Gaughan L, Dalgliesh C, El-Sherif A, Robson CN, Leung HY, Elliott DJ. The RNA-binding and adaptor protein Sam68 modulates signal-dependent splicing and transcriptional activity of the androgen receptor. Journal of Pathology 2008, 215(1), 67-77.
• Heer R, Robson CN, Shenton BK, Leung HY. The role of androgen in determining differentiation and regulation of androgen receptor expression in the human prostatic epithelium transient amplifying population (vol 2, pg 572, 2007). Journal of Cellular Physiology 2008, 215(1), 283-284.
• Moorman AV, Konn ZJ, Barber KE, Wright SL, Stewart ARM, Parker H, Richards SM, Kinsey SE, Eden OB, Vora AJ, Mitchell CD, Strefford JC, Harrison CJ. The Spectrum and Prognostic Relevance of Additional Abnormalities, Involving 12p and 21q, in Children with ETV6-RUNX1 Positive Acute Lymphoblastic Leukaemia (ALL). In: Abstracts of the 50th Annual Meeting of the American Society of Hematology. 2008, San Francisco, CA: Blood: American Society of Hematology.
• Heckman CA, Holopainen T, Wirzenius M, Keskitalo S, Jeltsch M, Herttuala SY, Wedge SR, Jürgensmeier JM, Alitalo K. The tyrosine kinase inhibitor cediranib blocks ligand-induced vascular endothelial growth factor receptor-3 activity and lymphangiogenesis. Cancer Research 2008, 68(12), 4754-4762.
• Martinez Soria N, Tussiwand R, Ziegler P, Manz MG, Heidenreich O. Transient depletion of RUNX1/RUNX1T1 by RNA interference delays tumour formation in vivo. Leukemia 2008, 23(1), 188-190.
• Scrace SF, Kierstan P, Borgognoni J, Wang LZ, Denny S, Wayne J, Bentley C, Cansfield AD, Jackson PS, Lockie AM, Curtin NJ, Newell DR, Williamson DS, Moore JD. Transient treatment with CDK inhibitors eliminates proliferative potential even when their abilities to evoke apoptosis and DNA damage are blocked. Cell Cycle 2008, 7(24), 3898-3907.
• An Q, Wright SL, Konn ZJ, Matheson E, Minto L, Moorman AV, Parker H, Griffiths M, Ross FM, Davies T, Hall AG, Harrison CJ, Irving JA, Strefford JC. Variable breakpoints target PAX5 in patients with dicentric chromosomes: a model for the basis of unbalanced translocations in cancer. Proceedings of the National Academy of Sciences of the United States of America 2008, 105(44), 17050-17054.
• Wedge SR, Jürgensmeier JM. VEGF receptor tyrosine kinase inhibitors for the treatment of cancer. In: Marmé, D and Fusenig, N, ed. Tumor Angiogenesis: Basic Mechanisms and Cancer Therapy. New York: Springer, 2008, pp.395-423.